Star Therapeutics, a biotechnology company focused on developing therapies for diseases with significant unmet need, has announced a private financing round totaling US$200 million. The financing was co-led by OrbiMed and Janus Henderson Investors and included participation from a broad group of healthcare investors. The new capital will support the company's next phase of growth, including the advancement of current preclinical programs into clinical development and continued pipeline expansion.
Financing and Use of Proceeds
Announced on October 23, 2026, the US$200 million financing was co-led by OrbiMed and Janus Henderson Investors. Other participants include Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, RA Capital Management, Redmile, Sofinnova Investments, Soleus Capital, and a leading sovereign wealth fund. Proceeds are designated to advance Star's current preclinical programs into the clinic and to support additional pipeline expansion.
Strategic Momentum
The financing closely follows Incyte's July 2026 acquisition of Star subsidiary Vega Therapeutics in a transaction valued at up to US$2 billion. That acquisition included Star's lead program latarcibart (VGA039), a novel monoclonal antibody in Phase 3 development for von Willebrand disease. Additionally, in September 2026, Star's spinout company Electra Therapeutics became a publicly traded company on Nasdaq under the ticker ETRA.
Investor Commentary
Carl L. Gordon, Ph.D., CFA, managing partner at OrbiMed, emphasized his experience working with the Star team across three different companies and their ability to identify important therapeutic opportunities. He expressed confidence that Star has the team, scientific approach, and pipeline needed to build on those achievements. Gordon noted that OrbiMed believes the company is well positioned for its next phase of growth.
Vish Sridharan, M.D., assistant portfolio manager and research analyst at Janus Henderson Investors, said Star stood out because of its team's strength and proven ability to invent and develop innovative therapies. He noted that Janus Henderson does not often invest in companies at this stage, which reflects the firm's conviction in Star's approach. Sridharan will join Star Therapeutics as a board observer.
Leadership Commentary
Adam Rosenthal, Ph.D., founder and chief executive officer of Star Therapeutics, stated that the company's mission is to develop best-in-disease therapies at scale for patients with significant unmet need. He described the financing as the next phase for Star and said it builds on the team's track record of discovering and developing novel medicines. Rosenthal added that the experienced team, growing pipeline, and support from top-tier investors position the company to improve patient outcomes.
Track Record and Pipeline
Star Therapeutics has established a track record of translating scientific insights into clinical-stage therapies. Members of its team have invented four first-in-class antibody therapies, including Enjaymo, the first approved drug for cold agglutinin disease, and three other therapies in Phase 3 development. The team has also contributed to four successful acquisitions, including Vega Therapeutics, DICE Therapeutics, True North Therapeutics, and iPierian.
With US$200 million in new financing and a strong syndicate of specialist investors, Star Therapeutics is positioned to advance its next-generation pipeline toward clinical development. The company's recent corporate milestones, including the Vega Therapeutics acquisition and Electra Therapeutics public listing, underscore its ability to create value through focused innovation. Star's continued expansion targets diseases with significant unmet need and aims to deliver life-changing therapies to patients.